Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway

Clinical Genetics

Volumn 83, Issue 1, 2013, Pages 88-91

  Moller P ^a   Maehle L ^a   Vabo A ^a   Clark, N ^a   Sun, P ^b   Narod, Sa ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1; Breast cancer; Penetrance

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NORTH AMERICA; NORWAY; POLAND; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NORWAY; PENETRANCE; RISK FACTORS;

EID: 84871196513     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01855.x     Document Type: Article

References (12)

1. Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005: 42: 602-603.
2. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003: 72: 1117-1130.
3. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998: 62: 676-689.
4. Lubinski J, Huzarski T, Byrski T et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 2011: DOI: 10.1002/ijc.26369.
5. Møller P, Mæhle L, Engebretsen LF et al. High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series. Hered Cancer Clin Pract 2010: 8 (1): 2.
6. Hagen AI, Kvistad KA, Maehle L et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007: 16 (4): 367-374.
7. Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 2003: 39 (15): 2205-2213.
8. Møller P, Heimdal K, Apold J et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001: 37 (18): 2428-2434.
9. Møller P, Hagen AI, Apold J et al. Genetic epidemiology av BRCA mutations - family history detects less than 50% of the mutation carriers. Eur J Cancer 2007: 43: 1713-1717.
10. Møller P, Clark N. CGEN-A clinical GENetics software application. Hum Mutat 2011: 32 (5): 537-542.
11. Finkelman BS, Rubinstein W, Friedman S et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (in press).
12. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008: 122: 2017-2022.